Enterprise Bank & Trust Co Purchases 791 Shares of GSK plc (NYSE:GSK)

Enterprise Bank & Trust Co boosted its stake in shares of GSK plc (NYSE:GSK) by 3.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,892 shares of the pharmaceutical company’s stock after purchasing an additional 791 shares during the quarter. Enterprise Bank & Trust Co’s holdings in GSK were worth $909,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. FMR LLC lifted its holdings in shares of GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after buying an additional 2,224,345 shares during the last quarter. Fisher Asset Management LLC grew its position in GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after acquiring an additional 870,449 shares during the period. Clifford Capital Partners LLC grew its position in GSK by 14.3% in the third quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock valued at $16,747,000 after acquiring an additional 51,378 shares during the period. Cerity Partners LLC grew its position in GSK by 61.8% in the third quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock valued at $17,728,000 after acquiring an additional 165,556 shares during the period. Finally, Natixis Advisors LLC grew its position in GSK by 20.0% in the third quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock valued at $20,460,000 after acquiring an additional 83,433 shares during the period. Institutional investors own 15.74% of the company’s stock.

GSK Stock Down 1.1 %

NYSE GSK traded down $0.37 during trading on Monday, hitting $32.72. The stock had a trading volume of 3,601,305 shares, compared to its average volume of 3,047,737. The company has a market capitalization of $67.81 billion, a PE ratio of 21.25, a P/E/G ratio of 1.52 and a beta of 0.63. GSK plc has a 12 month low of $32.55 and a 12 month high of $45.92. The company’s 50-day moving average price is $34.38 and its two-hundred day moving average price is $38.17. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Shareholders of record on Friday, November 15th were issued a $0.3928 dividend. This represents a $1.57 dividend on an annualized basis and a yield of 4.80%. This is a positive change from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend was Friday, November 15th. GSK’s dividend payout ratio is currently 95.45%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on GSK. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research report on Monday. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Seven research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.